{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-033455","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.134407+00:00","generated_at":"2026-06-04T13:54:07.828333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE","bullets":["Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.","Closed $200M PIPE in Feb 2024; pro-forma cash $403.5M to fund operations through at least 2026.","TYRA-300 Phase 1 SURF301 initial data expected 2H 2024; Phase 2 IND for achondroplasia on track for 2H 2024.","FDA granted Rare Pediatric Disease Designation for TYRA-300 in achondroplasia (Jan 2024).","Initiated SURF201 Phase 1 study for TYRA-200 in FGFR2-altered cholangiocarcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-033455","json":"https://secwatch.observer/filing/0000950170-24-033455.json","markdown":"https://secwatch.observer/filing/0000950170-24-033455.md","text":"https://secwatch.observer/filing/0000950170-24-033455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/tyra-20240319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:54:07.828333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d8e2bd5be606d9e26fb3ca172f9f2752f83e544","claim":"Tyra Biosciences, Inc. reported the fiscal year ended December 31, 2023 results: net income Full year 2023 net loss was $69.1 million.","evidence_excerpt":"Full year 2023 net loss was $69.1 million compared to $55.3 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"Full year 2023 net loss was $69.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a586a190ea71cbf0968c81c8a197f90eb94ddcda","claim":"Tyra Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss was $22.8 million.","evidence_excerpt":"Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Net income","value":"net loss was $22.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a73b4c88c4862bf2357f276b88ac8eed4077f011","claim":"Tyra Biosciences, Inc. reported the fourth quarter ended December 31, 2023 results: net income Fourth quarter 2023 net loss was $22.8 million.","evidence_excerpt":"Fourth quarter 2023 net loss was $22.8 million compared to $12.9 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000095017024033455/0000950170-24-033455-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Fourth quarter 2023 net loss was $22.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}